1458 GMT - Novo Nordisk's trial results for its new CagriSema weight-loss drug failed to impress, Stifel analyst Eric Le Berrigaud writes. This was the second phase 3 trial to evaluate CagriSema, this time in obese patients with diabetes. The type 2 diabetes population has a higher unmet need and CagriSema was expected to show a greater benefit in diabetic patients than in those without the disease. The results therefore remove a clear upside scenario, he says. "CagriSema does not seem to add a lot versus Eli Lilly's Tirzepatide either." Shares fall 3.2%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 11, 2025 10:58 ET (14:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。